Tisotumab Vedotin-tftv : Adis Evaluation

Clinical Considerations

- Antibody-drug conjugate targeting tissue factor, which is highly expressed on cervical cancer cells
- Has clinically meaningful tumor response rates and durability of response
- Has a tolerability profile that is manageable with preventive care, supportive care, and dose adjustments
- Premedication and required eye care are essential

Plain Language Summary

Background and rationale

- Cervical cancer is the fourth most common female malignancy. Recurrent or metastatic disease is associated with poor survival outcomes. While several cytotoxic treatment options are available for patients with recurrent or metastatic cervical cancer, response rates associated with these agents are low, and as such these patients represent an unmet medical need. Commonly in cervical cancer, tissue factor is highly expressed and has been linked to a poor prognosis; tissue factor is also the main initiator of the extrinsic coagulation pathway
- Tisotumab vedotin-tftv (TIVDAK®) is a tissue factor-directed antibody-drug conjugate

Clinical findings

- Administered as an intravenous infusion, tisotumab vedotin-tftv demonstrated clinically meaningful tumor response rates and durability of response in a clinical trial in patients with previously treated recurrent or metastatic cervical cancer
- Tisotumab vedotin-tftv had a manageable tolerability profile, with most adverse events being mild or moderate in severity and manageable with preventive care, supportive care, and dose adjustments

Conclusion

Tisotumab vedotin-tftv is a valuable treatment option for previously treated recurrent or metastatic cervical cancer